DOCARPAMINE

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H30N2O8S
Molecular Weight	470.537
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CCOC(=O)OC1=C(OC(=O)OCC)C=C(CCNC(=O)[C@H](CCSC)NC(C)=O)C=C1

InChI

InChIKey=ZLVMAMIPILWYHQ-INIZCTEOSA-N

InChI=1S/C21H30N2O8S/c1-5-28-20(26)30-17-8-7-15(13-18(17)31-21(27)29-6-2)9-11-22-19(25)16(10-12-32-4)23-14(3)24/h7-8,13,16H,5-6,9-12H2,1-4H3,(H,22,25)(H,23,24)/t16-/m0/s1

HIDE SMILES / InChI

Description

Docarpamine (marketed under the tradename Tanadopa) is a dopamine prodrug developed in Japan for the treatment of chronic heart failure. The drug does not cross the blood-brain barrier and shows no effect on CNS activity. It is supposed that the drug exerts its action by activating dopamine receptor D1.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine D1 receptor 106	Agonist 2,752

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic heart failure 21	Primary		Approved 8,583	TANADOPA

C_max

Value	Dose	Analyte	Population
63 ng/mL	750 mg single, oral	DOPAMINE plasma	Homo sapiens
53.1 ng/mL	750 mg single, oral	DOPAMINE plasma	Homo sapiens
62.6 ng/mL	750 mg 3 times / day multiple, oral	DOPAMINE plasma	Homo sapiens
76.8 ng/mL	750 mg single, oral	DOPAMINE plasma	Homo sapiens

AUC

Value	Dose	Analyte	Population
97 ng × h/mL	750 mg single, oral	DOPAMINE plasma	Homo sapiens
100.6 ng × h/mL	750 mg single, oral	DOPAMINE plasma	Homo sapiens
100 ng × h/mL	750 mg 3 times / day multiple, oral	DOPAMINE plasma	Homo sapiens
97.5 ng × h/mL	750 mg single, oral	DOPAMINE plasma	Homo sapiens

T_1/2

Value	Dose	Analyte	Population
0.7 h	750 mg single, oral	DOPAMINE plasma	Homo sapiens
0.8 h	750 mg single, oral	DOPAMINE plasma	Homo sapiens
0.8 h	750 mg 3 times / day multiple, oral	DOPAMINE plasma	Homo sapiens
0.8 h	750 mg single, oral	DOPAMINE plasma	Homo sapiens

F_unbound

Value	Dose	Co-administered	Analyte	Population
59.5%			DOCARPAMINE serum	Homo sapiens

Doses

Doses

Show entries

Dose	Population	Adverse events
1500 mg single, oral Highest studied dose	healthy, ADULT
750 mg 4 times / day multiple, oral Highest studied dose	unhealthy, ADULT

Showing 1 to 2 of 2 entries

Previous1Next

PubMed

Show entries

Title	Date	PubMed
A novel orally active dopamine prodrug TA-870. I. Renal and cardiovascular effects and plasma levels of free dopamine in dogs and rats.	1989 Jun	2484082
A novel orally active dopamine prodrug TA-870. III. Positive inotropic effect and cardiorenal selectivity in anesthetized dogs.	1990 Feb	1689425